The TNF alfa in the treatment of rheumatoid arthritis;Les modulateurs du TNFα dans le traitement de la polyarthrite rhumatoide

Tunisie Medicale

Volumn 82, Issue 10, 2004, Pages 893-904

  Kochbati, Samir ^a   Boussema, Fatma ^a   Ben Miled, Mohamed ^a   Ktari, Sonia ^a   Daoud, Lilia ^a   Ben Rhouma, Samir ^a   Ben Amor, Golsom ^a   Chérif, Ouahida ^a   Rokbani, Lilia ^a  

^a HABIB THAMEUR HOSPITAL   (Tunisia)

Author keywords

Efficacy; Immunomodulators, TNF alfa inhibitors; Rheumatoid arthritis; Tolerance

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; CD4 ANTIGEN; CERTOLIZUMAB PEGOL; ETANERCEPT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G1; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 6; INTERLEUKIN 8; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; ANTIBODY;

AUTOIMMUNE DISEASE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INFECTION; NEOPLASM; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYSTEMATIC REVIEW; DRUG ANTAGONISM; IMMUNOLOGY;

ANTIBODIES; ARTHRITIS, RHEUMATOID; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 11344270727     PISSN: 00414131     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. - Sany J, Combe B, Jorgensen C. Immunopathologie et pathogénie de la polyarthrite rhumatoïde II. Encycl Méd Chir(éditions scientifiques et médicales Elsevier SAS, Paris), Appareil locomoteur, 14-220-A-15, 1997: 1-4
2. - Dayer JM. Modulation de l'arthrite inflammatoire. Rhumatologie en Europe 1998; 28-31
3. - Feldman m, Brennan Fm, Maini Rn Role of cytokins in rheumatoid arthritis Annu rev Immunol 1996; 14, 397-440
4. - Moreland LW. Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol 1999; 24 Suppl 57: 7-15.
5. - Sany J Nouvelles biothérapies dans le traitement de lo polyarthrite rhumatoïde. Rev Rhum [Ed Fr] 1999; 66: 625-37.
6. Keenan GF, Clark J, Baker DG, Jones S. The rare occurrence of fungal infections is patients receiveing infliximab. Arthritis Rheum 2001; 44(suppl): S82
7. Feldmann M, Bondeson J, Brennman FM, Foxwell BMJ, Maini RN The rationale for the current boom in anti-TNFa treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNF and minimise hazards? Ann Rheum Dis 1999; 58 Suppl 1: 127-31.
8. Kavanaugh A. Anti-tumor necrosis factor a monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am 1998; 24: 593-614
9. Sany. J. modulation du TNFa dans le traitement de la polyarthrite rhumatoïde. Lettre du rhumatologue 1998; 252: 4-6
10. Wendling D, Toussirote. Les thérapeutiques ciblés anti-TNFa dans la polyarthrite rhumatoïde. Rev. Rhum 1999; 66: 211-6
11. Combe B. Le thalidomide: vers de nouvelles indications? Rev. Rhum Mal Ostéoarctic 2001, 68: 951-957
12. Sany J, Kaiser mj Les agents anti-TNF a dans le traitement de la polyarthrite rhumatoïde. Ann med Int 2002, 153, 34-40
13. Sany J. Quand commencer et comment surveiller un traitement par un agent anti-TNF a au cours de la polyarthrite rhumatoïde? Rev Rhum 2001, 68: 115-165
14. Elliot MJ, Maini RN, Feldman M, Kalden Jr, Antoni C, Smolen JS et Al. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor a(cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-1110
15. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, MacFarlane JD et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low dose weekly methotrexate in rhumatoid arthrits. Arthritis rheum 1998, 41, 1552-62
16. Elliot MJ, Maini RN, Feldman M, Long Fox A, Cahrles P, Bij H et al. Repeated therapy with monoclonal anti body to tumor necrosis factor a(ca2) in patients with rheumatoid arthrits. Lancet 1994, 344, 1125-1127
17. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, MacFarlane JD et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low dose weekly methotrexate in rhumatoid arthrits. Arthritis rheum 1998, 41, 1552-62
18. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, MacFarlane JD et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low dose weekly methotrexate in rhumatoid arthritis. Arthritis rheum 1998, 41, 1552-1563
19. Maini RN, St clair EW, Breedveld FC, Furst DE, Kalden JR, Weisman M et al. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal anti body) versus placebo in rhumatoid arthritis patients receiveing concomitant methotrexate: a randomised phase III trial. Lancet 1999, 354: 1932-1939
20. Lipsky P, St Clair EW, Furst D, Breedveld F, Smoln J, Kalden, et al. 54 week clinical and radiographic results from the ATTRACT trial: a phase III study of infliximab(remicade) in patients with active RA despite methotrexate[abstract]. Arthritis Rheum 1999, 42 Suppl 9: 1980
21. Lipsky V, Van Der Heidge D, St Claire W, Smolen J, Furst D, Kalden J et al. 102 week clinical and radiological results from the ATTRACT trial: a year randomised, controlled, phase III trial infliximab(remicade) in patients with active RA despite methotrexate. Arthritis Rheum 2000, 43(suppl)
22. Richar-Miceli C, Mailefert JF, Dougados M Pertinence clinique sous anti TNF au cours de la polyarthrite rhumatoïde Rev Rheum 2001, 68(suppl)
23. Rau R, Sander O, Den Broeder A, Van Riel P, Van De Putte L, Kruger K, et al. Long term efficacy and tolerability of multiple IV doses of the fully human anti TNF antibody D2E7 in patient with rheumatoid arthritis[abstract]. Arthritis Rheum 1998, 41 suppl 9: 137
24. Van De Putte L, Rau R, Breedveld FC, Kalden JR, Maladise MG, Schattenkirchner et al. Efficacy of the fully human anti TNF antibody D2E7 in rhumatoid arthritis[abstract]. Arthritis Rheum 1999, 42 suppl: 1977
25. Van De Putte LB, Van Riel PL, Den Broeder A, Sander O, Rau R, Binder C et al. A single dose placebo controlled phase I study of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis. Arthritis Rheum 1999; 42 (suppl): S57
26. Keystone E, Weinblatt M, Furst De, Weisman M, Moreland L, Birbara C et al. The ARMADA trial: a double-blind placebo controlled trial of the fully human anti TNF monoclonal antibody, adalimumab D2E7 in patients with active RA on methotrexate MTX. Arthritis Rheum 2001, 44 suppl: S213
27. Keystone E, Choy E, Kalden J, Klareskog L, Sany J, Smolen J et al. CDP-870 A novel, pegylated, humanised TNF inhibitor is effective in treating the signs and symptoms of rhumatoid arthritis. ACR annual meeting San Francisco, Nov 10-15, 2001 (abstract LB3)
28. Lovel DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JS et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000, 342: 763-769
29. Jarvis R, Faulds D, Etanercept. A review of its use in rheumatoid arthritis. Drugs 1999, 57: 945-966
30. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL. Treatment of rheumatoid arthritis with a recombinant human necrosis factor receptor (p75) Fc fusion protein. N Engl J Med 1997; 337: 141-147
31. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL et al. Treatment of rheumatoid arthritis with a recombinant human necrosis factor receptor (p75) Fc fusion protein. N Engl J Med 1997; 337: 141-147
32. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt BJ et al. Etanercept therapy in rheumatoid arthritis. Ann intern Med 1999; 130: 478-86
33. Finck B, Martin R, Fleischmann, Moreland L, Schiff J. A phase III trial of entercept us methotrexate MTX in early rheumatoid arthritis (enbrel era trial) [abstract]. Arthritis Rheum 1999; 42 suppl 9: 280
34. Bathon JM, Martin RW, Fleischman RM, Tesser JR, Schiff MH, keystone ec et al. A comparison of etanercept and methotrxate in patients with early rhumatoid arthritis. N Engl J Med 2000; 343: 1586-1593
35. Weinblatt ME, Kremer JM; Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9
36. Weinblatt ME, Kremer JM, Lange M. Long term safety and efficacy of combination therapy with methotrexate MTX and etanercept (enbrel) [abstract]. Arthritis Rheum 1999; suppl 9: 1982
37. Mugnier B, Bouventog. Les anticorps monoclonaux anti TNFalpha dans le traitement de la polyarthrite rhumatoïde. Rev med interne 2000, 21: 854-62
38. Moreland LW, Cohen SB, Baumgartner S, Sciff M, Tindall EA. Long term use of etanercept in patients with DMARD-refactory rheumatoid arthritis[abstract]. Arthritis Rheum 1999; 42 suppl 9: 1981
39. Palazzo E, Hamza S. Les nouveaux traitements de fond de la polyarthrite rhumatoïde. Actualité rhumatologique 2000
40. Arkham A, Lamb HM. Infliximab: a review of its uses in the management of rheumatoid arthritis. Drugs 2000; 59: 1341-1359
41. Feldmann M, Elliot MJ, Voody JN, Mainl RN. Anti tumor necrosis factor, therapy of rheumatoid arthritis. Immunol 1997; 64: 283-350
42. Kavanaugh A, Keenan G, De Woody K, Marsters P, Hendricks D, Clark J et al. Long term follow-up of patients treated with infliximab in clinical trials. Arthritis rheum 2001; 44 suppl9: S81
43. Kavanaugh A, Maini R, De Woody K, Masters P, Dittrich K, Harriman G et al. Long-term follow-up of patients treated with infliximab (anti TNF antibody) in clinical trial. Arthritis Rheum 1999; 42(suppl9): 1979
44. Lipsky PE, Van Der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J med 2000; 343: 1594-1602
45. Baker DG, Clark J, Keenan GF. Tuberculosis occuring in patients receiving the anti TNF agent infliximab. Arthritis Rheum 2001; 44suppl: S105
46. Keane J, Gerrshons, Wise RP, Mirabile-Levens, Schwieterman WD et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha neutralizing agent. N Engl J Med 2001; 3456: 1098-1104
47. GTI (groupe tuberculose et infliximab) Affsaps. Recommandations concernant la prévention et la prise en charge des tuberculoses survenant sous infliximab. Rev Rhum 2002, 69: 256-259
48. Moreland LW, Cohen SB Baumgartner SW, Tindall EA, Bulpitt K, Martin R et al. Long term safety and efficacy of etanercept in patients with rheumatoid arthritis. J. Rhumatol 2001, 28: 1238-44
49. B Combe. Traitement anti "tumor necrosis factor" (TNF) dans la polyarthrite rhumatoïde. EMC, app locomoteur 2002, Fa 14-220-A20
50. Charles PJ, Smeenk RJ, De Lang J, Feldmann M, Maini RN. Assessment of antibodies to double-stranted DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomised placebo controlled trials). Arthritis Rheum 200; 43: 2383-2390
51. Pisetsky DS Tumor necrosis factor alpha blockers and the induction of anti DNA auto-antibodies Arthritis Rheum 2000, 43: 2381-2
52. Wagner LC, Schantz AR, Lasorda JA, Dinota DR, Wang H, Marsters PR et al. Human anti-chimeric antibody(HACA) reponses to infliximab(remicade) in the ATTRACT clinical study of patients with active rhumatoid arthritis (abstract). Arthritis Rheum 1999; 42suppl 9: 73
53. Kahan A Anti TNFalpha: résultats des essais cliniques Rev Rhum 2001; 68(suppl1): 215-65
54. Sany J Les inhibiteurs du TNFalpha dans le traitement de la polyarthrite rhumatoïde. Lettre du rhumatologue 2000: suppl266: 17-23
55. Brion PH, Mittal-Henkle A, Kalunian KC. Autoimmune skin rashes associated with etanercept for rhumatoid arthritis[letter]. Ann Intern Med 1999; 131: 634
56. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurological events reported in association with tumor necrosis factor antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis rheum 2001; 44: 1977-1983
57. Furst DE, Breedveld FC, Burmester GR, Crofford R, Emery P, Feldman M et al. Consensus statement: acces to disease modifying treatments for rhumatoid arthritis patients. Ann rheum Dis 1999; 58 (suppl1): 129-130
58. Furst DE, Keystone E, Breedveld FC, Kalden JR, Smalen JS, Antoni CE et al. Updated consensus statement an tumor necrosis factor blocking agents for the treatment on tumor necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases. Ann Rheum Dis 2001; 60 suppl3: 2-5
59. Emery P, Reginster JY, Appelboom T, Breedveld F, Edelmann F, Kekow J et al. Who collaborating centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis. Rheumatology 2001; 40: 699-702
60. Prevoo ML, Vant Hof MA, Kuper HH, Van Leewen MA, Van De Putte LB, Van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Arthritis Rheum 1995; 38: 44-48
61. Smolen JS, Breedveld FC, Burmester GR, Combe B, Emery P, Kalden JR et al. Consensus statement on the initiation and continuation of TNF blocking therapies in rhumatoid arthritis. Ann Rheum Dis 2000; 59: 504-505
62. Silman A, Klareskog L. Proposal to establish a register for the long term surveillance of adverse events in patients with rheumatic diseases exposed to biological agents: the EULAR surveillance register for biological compounds. Ann Rheum Dis 2000; 59: 419-420